Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3889-3895

  Wu, Wenting ^a   Zhang, Wei ^b   Qiao, Rong ^b   Chen, Dan ^a   Wang, Huibo ^a,c   Wang, Yi ^a   Zhang, Shuyu ^a   Gao, Ge ^a   Gu, Aiqin ^b   Shen, Jie ^b   Qian, Ji ^a   Fan, Weiwei ^a   Jin, Li ^a   Han, Baohui ^b   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHINESE; CODON; COMBINATION CHEMOTHERAPY; DNA REPAIR; EXCISION REPAIR; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DRUG TOXICITY; FEMALE; GASTROINTESTINAL DISEASES; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LEUKOPENIA; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 66649120041     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2715     Document Type: Article

References (34)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717 (Pubitemid 27260107)
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
4. Carbone DP, Minna JD. Chemotherapy for non-small cell lung cancer. BMJ 1995;311:889-890
5. Bunn PA, Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100 (Pubitemid 28213318)
6. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
7. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-775 (Pubitemid 28427226)
8. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279 (Pubitemid 37487159)
9. Danesi R, de Braud F, Fogli S, et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003;55:57-103. (Pubitemid 36268399)
10. van de Vaart PJ, Belderbos J, de Jong D, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000;89:160-166 (Pubitemid 30185925)
11. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534-1538 (Pubitemid 40315237)
12. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-2601 (Pubitemid 41103746)
13. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis 2000;21:453-460 (Pubitemid 30137930)
14. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 1999;8:77-81. (Pubitemid 29090873)
15. Yin J, Li J, Ma Y, Guo L, Wang H, Vogel U. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett 2005;223:219-226 (Pubitemid 40719620)
16. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654-8658 (Pubitemid 34013872)
17. Qiao Y, Spitz MR, Guo Z, et al. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 2002;509:165-174 (Pubitemid 35341459)
18. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-1169 (Pubitemid 37414228)
19. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434 (Pubitemid 34112296)
20. Gazdar AF. DNA repair and survival in lung cancer - the two faces of Janus. N Engl J Med 2007;356:771-773 (Pubitemid 46294609)
21. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000;57:1229-1235 (Pubitemid 30663480)
22. Wang Z, Xu B, Lin D, et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 2008.
23. An J, Liu Z, Hu Z, et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 2007;16:1633-1638
24. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-1203 (Pubitemid 39199306)
25. Caggana M, Kilgallen J, Conroy JM, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 2001;10:355-360 (Pubitemid 32703220)
26. Powell JR, Moriyama EN. Evolution of codon usage bias in Drosophila. Proc Natl Acad Sci U S A 1997;94:7784-7790 (Pubitemid 27343726)
27. Vogel U, Hedayati M, Dybdahl M, Grossman L, Nexo BA. Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis 2001;22:899-904. (Pubitemid 32514955)
28. Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 2000;461:197-210.
29. Liang G, Xing D, Miao X, et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003;105:669-673 (Pubitemid 36687735)
30. Winsey SL, Haldar NA, Marsh HP, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000;60:5612-5616
31. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002;128:1084-1088
32. Lenth RV. Statistical power calculations. J Anim Sci 2007;85:E24-9.
33. Cleophas TJ, Zwinderman AH. Clinical trials: how to assess confounding and why so. Curr Clin Pharmacol 2007;2:129-133 (Pubitemid 46813421)
34. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007;13:2876-2881 (Pubitemid 46849561)